Understanding how specific NRAS mutations interact with BRAF in melanoma
Official title: Defining the biochemical properties and implications of NRAS mutant-specific BRAF interactions in melanoma
Funded at Ohio State University · NIH-10826520 · Data updated 2026-11-12
This study is looking at how certain changes in the NRAS gene interact with BRAF proteins in melanoma, which is a type of skin cancer, to help us understand how these changes might make the cancer grow and resist treatment.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $37,594 |
| NIH project number | 1F31CA288053-01 |
| Project ID | NIH-10826520 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are melanoma patients who have been identified with NRAS mutations.
✕Less likely to help
Patients without NRAS mutations or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the biochemical interactions between specific NRAS mutations and BRAF proteins in melanoma, a type of skin cancer. By examining how these mutations affect cellular signaling pathways that promote cancer growth, the study aims to uncover the mechanisms that drive melanoma development. The approach includes molecular dynamics simulations and experimental assays to analyze the binding properties of NRAS mutants with BRAF. This could lead to a better understanding of how these mutations contribute to cancer progression and treatment resistance.
Why it matters
Potential benefit: If successful, this research could lead to more targeted therapies for melanoma patients with specific NRAS mutations.
How similar studies have gone: Previous research has shown promising results in understanding RAS mutations in cancer, indicating that this approach could yield valuable insights.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Lew, Rachel E. — Ohio State University
- Study coordinator: Lew, Rachel E.
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.